Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone310-358-3200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.67 million
Profitability
Miscellaneous
Employees40
OptionableNot Optionable
Capricor Therapeutics (NASDAQ:CAPR) Frequently Asked Questions
What is Capricor Therapeutics' stock symbol?
Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR."
How were Capricor Therapeutics' earnings last quarter?
Capricor Therapeutics Inc (NASDAQ:CAPR) announced its quarterly earnings results on Thursday, August, 9th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.01. The biotechnology company had revenue of $0.40 million for the quarter, compared to analysts' expectations of $0.41 million. Capricor Therapeutics had a negative return on equity of 159.36% and a net margin of 24.75%. View Capricor Therapeutics' Earnings History.
When is Capricor Therapeutics' next earnings date?
What price target have analysts set for CAPR?
2 Wall Street analysts have issued 1-year price objectives for Capricor Therapeutics' shares. Their predictions range from $3.50 to $4.00. On average, they anticipate Capricor Therapeutics' stock price to reach $3.75 in the next year. This suggests a possible upside of 790.5% from the stock's current price. View Analyst Price Targets for Capricor Therapeutics.
What is the consensus analysts' recommendation for Capricor Therapeutics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Capricor Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Capricor Therapeutics.
What are Wall Street analysts saying about Capricor Therapeutics stock?
Here are some recent quotes from research analysts about Capricor Therapeutics stock:
- 1. Maxim Group analysts commented, "Capricor announced it has resumed dosing in the HOPE-2 trial, which is testing CAP-1002 for already enrolled patients (n=20) with Duchenne muscular dystrophy (DMD)." (2/6/2019)
- 2. According to Zacks Investment Research, "Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. " (1/21/2019)
- 3. HC Wainwright analysts commented, "Valuation and potential impediments to achieving it. We reiterate our Buy rating and $8.60 price target. Our price target is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, CAP-1002 in DMD patients. We believe this method is appropriate in capturing the value of the clinical stage pipeline by allowing us to flex multiple assumptions, including chance of success, peak sales estimates, and year of commercial launch." (11/20/2018)
Has Capricor Therapeutics been receiving favorable news coverage?
News coverage about CAPR stock has been trending somewhat negative on Thursday, InfoTrie reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Capricor Therapeutics earned a media sentiment score of -1.7 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days.
Who are some of Capricor Therapeutics' key competitors?
Some companies that are related to Capricor Therapeutics include Evoke Pharma (EVOK), Scpharmaceuticals (SCPH), CTI BioPharma (CTIC), Vaccinex (VCNX), Arcturus Therapeutics (ARCT), Generex Biotechnology (GNBT), Vascular Biogenics (VBLT), Bellerophon Therapeutics (BLPH), Vistagen Therapeutics (VTGN), Novus Therapeutics (NVUS), DiaMedica Therapeutics (DMCAF), Selecta Biosciences (SELB), Achaogen (AKAO), BIOLINERX LTD/S (BLRX) and PLx Pharma (PLXP).
Who are Capricor Therapeutics' key executives?
Capricor Therapeutics' management team includes the folowing people:
- Frank I. Litvack M.D., Independent Executive Chairman of the Board (Age 59)
- Linda Marban Ph.D., President, Chief Executive Officer, Director (Age 51)
- Anthony Bergmann, Chief Financial Officer, Principal Accounting Officer (Age 32)
- Karen G. Krasney J.D., Executive Vice President, General Counsel (Age 62)
- Thomas Lyle Copmann Ph.D., Vice President - Regulatory Affairs and Drug Development (Age 61)
- Houman Hemmati M.D., Ph.D., Vice President - Medical & Clinical Development, New Therapies
- Luis Rodriguez-Borlado Ph.D., Vice President - Regenerative Therapies
- Rachel Smith Ph.D., Vice President - Research & Development (Age 36)
- Deborah Ascheim M.D., Chief Medical Officer
- Joshua A. Kazam, Director (Age 40)
Who are Capricor Therapeutics' major shareholders?
Capricor Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Brown Advisory Inc. (2.74%). Company insiders that own Capricor Therapeutics stock include Louis Manzo and Sinai Medical Center Cedars. View Institutional Ownership Trends for Capricor Therapeutics.
Which institutional investors are selling Capricor Therapeutics stock?
How do I buy shares of Capricor Therapeutics?
Shares of CAPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Capricor Therapeutics' stock price today?
One share of CAPR stock can currently be purchased for approximately $0.4211.
How big of a company is Capricor Therapeutics?
Capricor Therapeutics has a market capitalization of $13.08 million and generates $2.67 million in revenue each year. The biotechnology company earns $2.43 million in net income (profit) each year or ($0.44) on an earnings per share basis. Capricor Therapeutics employs 40 workers across the globe.
What is Capricor Therapeutics' official website?
How can I contact Capricor Therapeutics?
Capricor Therapeutics' mailing address is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. The biotechnology company can be reached via phone at 310-358-3200 or via email at [email protected]
MarketBeat Community Rating for Capricor Therapeutics (NASDAQ CAPR)
MarketBeat's community ratings are surveys of what our community members think about Capricor Therapeutics and other stocks. Vote "Outperform" if you believe CAPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CAPR will underperform the S&P 500 over the long term. You may vote once every thirty days.
